Differential (Click to cross reference) adverse drug reaction anticonvulsants anticonvulsants, effectiveness anticonvulsants, selection of ataxia cannabidiol cannabinoids cerebellar ataxia, children children chromosomal abnormality chromosome 2 cognition complications developmental retardation Dravet syndrome electroencephalogram, abnormalities of encephalopathy familial fenfluramine fever gait disorder gene mutation genetic neurologic disorders intellectual deficit marihuana mortality myoclonic jerks myoclonus myoclonus, epilepsy prognosis progressive neurologic disorder psychomotor retardation pyramidal tract dysfunction review article SCN1A gene seizure seizure, children seizure, drug resistance seizure, familial seizure, febrile seizure, intractable seizure, neonatal seizure, paradoxical seizure, photosensitive seizure, tonic-clonic seizure, treatment of sodium channel dysfunction status epilepticus topiramate treatment of neurologic disorder walking, difficulty with

Showing articles 0 to 6 of 6 FDA Approves Fenfluramine for Treatment of Seizures Associated with Dravet Syndrome FDA June2020, , 2020 Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome NEJM 376:2011-2020, Devinsky, O.,et al, 2017 Progressive Gait Deterioration in Adolescents with Dravet Syndrome Arch Neurol 69:873-878, Rodda, J.M.,et al, 2012 Clinical Spectrum of Mutations in SCN1A Gene: Severe Myoclonic Epilepsy in Infancy and Related Epilepsies Epilepsy Res 70S:S223-S230, Fujiwara,T., 2006 Epilepsy Syndromes in Infancy Pediatr Neurol 34:253-263, Korff,C.M. &Nordii,D.R.,Jr., 2006 Clinical Correlations of Mutations in the SCN1A Gene: From Febrile Seizures to Severe Myoclonic Epilepsy in Infancy Pediatr Neurol 30:236-243, Ceulemans,B.P.G.M.,et al, 2004 Showing articles 0 to 6 of 6